The American Academy of Ophthalmology has released a statement warning Congress of the unintended results of the proposed Pharmaceutical Compounding Quality and Accountability Act, which seeks to crack down on oversights of compounding pharmaceuticals.
The AAO is largely supportive of the bill, S. 959, but calls for exemption from provisions that require specific patient designation for biological products and marketed drugs. The Academy argues there is no evidence linking safe repackaging processes with the use of a patient's name when labeling a drug.
More Articles on Ophthalmology:
Dr. Judy Meyers Joins Ophthalmology Associates in Fort Worth
ARVO Names Dr. Justine Smith President, Dr. William Mieler President-Elect
8 Recent Eye Surgery Center Openings, Mergers & Acquisitions
The AAO is largely supportive of the bill, S. 959, but calls for exemption from provisions that require specific patient designation for biological products and marketed drugs. The Academy argues there is no evidence linking safe repackaging processes with the use of a patient's name when labeling a drug.
More Articles on Ophthalmology:
Dr. Judy Meyers Joins Ophthalmology Associates in Fort Worth
ARVO Names Dr. Justine Smith President, Dr. William Mieler President-Elect
8 Recent Eye Surgery Center Openings, Mergers & Acquisitions